All entries on GSK across all areas, newest first. tag:eurotrack.ai,2026:en:en/companies/gsk 2026-10-14T06:00:00Z Eurotrack tag:eurotrack.ai,2026:8765b553:en 2026-10-14T06:00:00Z

On 14 October 2026 GSK told a special works council about a restructuring in Belgium that would remove 1,217 jobs at its Walloon sites in Wavre, Rixensart and Gembloux, including 482 office and 735 managerial positions; blue-collar workers are exempt and the cuts are to run over two years. R&D, production and international support functions are affected; GSK employs about 8,500 people in Belgium. Unions had expected around 800 jobs; Setca and Solidaris criticised the plan on 16 October 2026 (VRT NWS, 14 Oct 2026; second source: La Dernière Heure, 16 Oct 2026). — Sources: https://www.vrt.be/vrtnws/en/2026/10/14/over-1-200-jobs-at-risk-at-vaccine-manufacturer-gsk/ · https://www.dhnet.be/dernieres-depeches/2026/10/16/gsk-les-licenciements-chez-gsk-consequence-dune-course-aux-surprofits-HZ4XVFHQ6BDG5DLLRMWKOGDYQI/

tag:eurotrack.ai,2026:7f289e90:en 2026-07-15T06:00:00Z

UK pharma group GSK completed its acquisition of US oncology specialist Nuvalent on 15 July (equity value approx. $10.6bn, approx. $9.4bn net of cash). GSK gains three lung-cancer assets, two of them under FDA review (PDUFA dates September/November 2026). Source is the SEC 6-K filing; second source: Investing.com. — Source: https://www.sec.gov/Archives/edgar/data/0001131399/000165495426006663/a5060m.htm